These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25111500)

  • 41. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
    Prasuhn J; Prasuhn M; Fellbrich A; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Münte TF; Hanssen H; Heldmann M; Brüggemann N
    Neurology; 2021 Sep; 97(10):e1007-e1016. PubMed ID: 34187859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuromelanin, neuroleptics and schizophrenia: hypothesis of an interaction between noradrenergic and dopaminergic system.
    Kaiya H
    Neuropsychobiology; 1980; 6(5):241-8. PubMed ID: 6106167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia.
    van der Pluijm M; Wengler K; Reijers PN; Cassidy CM; Tjong Tjin Joe K; de Peuter OR; Horga G; Booij J; de Haan L; van de Giessen E
    Am J Psychiatry; 2024 Jun; 181(6):512-519. PubMed ID: 38476044
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microstructural abnormalities of substantia nigra in Parkinson's disease: A neuromelanin sensitive MRI atlas based study.
    Safai A; Prasad S; Chougule T; Saini J; Pal PK; Ingalhalikar M
    Hum Brain Mapp; 2020 Apr; 41(5):1323-1333. PubMed ID: 31778276
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subtypes evaluation of motor dysfunction in Parkinson's disease using neuromelanin-sensitive magnetic resonance imaging.
    Xiang Y; Gong T; Wu J; Li J; Chen Y; Wang Y; Li S; Cong L; Lin Y; Han Y; Yin L; Wang G; Du Y
    Neurosci Lett; 2017 Jan; 638():145-150. PubMed ID: 27993708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density.
    Kawaguchi H; Shimada H; Kodaka F; Suzuki M; Shinotoh H; Hirano S; Kershaw J; Inoue Y; Nakamura M; Sasai T; Kobayashi M; Suhara T; Ito H
    PLoS One; 2016; 11(3):e0151191. PubMed ID: 26954690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The utility of the combined use of
    Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
    Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Parkinson's disease by neuromelanin-sensitive magnetic resonance imaging and
    Kuya K; Ogawa T; Shinohara Y; Ishibashi M; Fujii S; Mukuda N; Tanabe Y
    Acta Radiol; 2018 May; 59(5):593-598. PubMed ID: 28743197
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease?
    Okuzumi A; Hatano T; Kamagata K; Hori M; Mori A; Oji Y; Taniguchi D; Daida K; Shimo Y; Yanagisawa N; Nojiri S; Aoki S; Hattori N
    Eur J Neurol; 2019 Nov; 26(11):1408-1416. PubMed ID: 31136060
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach.
    Chen X; Huddleston DE; Langley J; Ahn S; Barnum CJ; Factor SA; Levey AI; Hu X
    Magn Reson Imaging; 2014 Dec; 32(10):1301-6. PubMed ID: 25086330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging.
    Moon WJ; Park JY; Yun WS; Jeon JY; Moon YS; Kim H; Kwak KC; Lee JM; Han SH
    Korean J Radiol; 2016; 17(5):633-40. PubMed ID: 27587951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Substantia nigra neuromelanin magnetic resonance imaging in patients with different subtypes of Parkinson disease.
    Wang L; Yan Y; Zhang L; Liu Y; Luo R; Chang Y
    J Neural Transm (Vienna); 2021 Feb; 128(2):171-179. PubMed ID: 33559725
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuromelanin? MRI of Noradrenergic and Dopaminergic Neurons.
    Watanabe T
    J Magn Reson Imaging; 2023 Jul; 58(1):328-329. PubMed ID: 36282617
    [No Abstract]   [Full Text] [Related]  

  • 57. Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.
    Xing Y; Sapuan A; Dineen RA; Auer DP
    Mov Disord; 2018 Nov; 33(11):1792-1799. PubMed ID: 30423212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reproducibility of locus coeruleus and substantia nigra imaging with neuromelanin sensitive MRI.
    Langley J; Huddleston DE; Liu CJ; Hu X
    MAGMA; 2017 Apr; 30(2):121-125. PubMed ID: 27687624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease.
    Isaias IU; Trujillo P; Summers P; Marotta G; Mainardi L; Pezzoli G; Zecca L; Costa A
    Front Aging Neurosci; 2016; 8():196. PubMed ID: 27597825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cross-Scanner Harmonization of Neuromelanin-Sensitive MRI for Multisite Studies.
    Wengler K; Cassidy C; van der Pluijm M; Weinstein JJ; Abi-Dargham A; van de Giessen E; Horga G
    J Magn Reson Imaging; 2021 Oct; 54(4):1189-1199. PubMed ID: 33960063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.